Rchr

J-GLOBAL ID：200901037068719045 Update date: Sep. 04, 2024

Seimiya Hiroyuki

セイミヤヒロユキ | Seimiya Hiroyuki

Affiliation and department：
Job title： Member and Chief
Homepage URL (2)： https://www.jfcr.or.jp/chemotherapy/department/molecular_biotherapy/ , https://www.k.u-tokyo.ac.jp/en/gsfs/faculty/hiroyuki_seimiya/

Research field (6)： Tumor biology , Tumor diagnostics and therapeutics , Pharmacology , Pharmaceuticals - health and biochemistry , Cell biology , Molecular biology

Research keywords (36)： Chemical Biology , G4 ligand , Inhibitor , Biomarker , Pharmacodynamics , β-catenin , APC , Xenograft , Tumor suppressor gene , DNA repair , Genomic instability , Anticancer drug , Drug discovery , Tumor , Cancer , Drug screening , Cell division , Chromosome , Wnt signal , Cell immortalization , Cell growth , Drug resistance , Synthetic lethality , DNA damage , Chemotherapy , Predictive biomarker , Cellular senescence , Molecular profiling , Poly(ADP-ribosyl)ation , G-quadruplex , Molecular targeted therapy , Cancer stem cells , PARP , Tankyrase , Telomerase , Telomere

Research theme for competitive and other funds (49)：

2022 - 2028 生命科学連携推進協議会
2022 - 2028 先端モデル動物支援プラットフォーム
2022 - 2025 ポリADPリボシル化酵素タンキラーゼを標的としたがん精密医療の分子基盤
2021 - 2025 Investigation of novel molecular targets for oral cancer stem cells and establishment of novel oral cancer treatment strategy
2023 - 2025 Development of cancer medicine targeting G-quadruplex-mediated regulation of translation

2022 - 2025 切除不能進行・再発大腸がんを対象としたタンキラーゼ阻害剤の医師主導第I相治験

2022 - 2024 グアニン四重鎖による翻訳制御に潜むがん細胞選択的な脆弱性

2021 - 2023 Development of cancer medicine targeting G-quadruplex-mediated regulation systems of genomic function

2020 - 2022 Molecular basis for cancer cell-specific vulnerability to disturbance of G-quadruplex dynamics

2019 - 2022 Optimization of cancer therapeutic strategies that target tankyrase-specific PARylation

2020 - 2022 Elucidating the functions of quadruplex nucleic acids by integrative molecular profiling of chemical signals

2019 - 2022 進行性大腸がんに対する革新的治療薬としてのタンキラーゼ阻害剤の開発

2019 - 2021 難治がん治療薬としてのグアニン四重鎖リガンドの開発

2016 - 2021 先端モデル動物支援プラットフォーム

2018 - 2020 非典型核酸形態が惹起するがん種横断的脆弱性の分子基盤と治療応用

2018 - 2020 Integrative functional analysis of G-quadruplex nucleic acids by utilizing natural and synthetic chemical tool molecules

2018 - 2020 非典型核酸形態が惹起するがん種横断的脆弱性の分子基盤と治療応用

2016 - 2019 Synthetic lethality-based identification of drug-sensitive genome profiles

2016 - 2019 テロメア制御因子を標的とした革新的がん治療法の開発

2014 - 2016 Regulation of cell motility by poly(ADP-ribosyl)ation and its application to overcoming cancer invasion and metastasis

2013 - 2016 Development of G-quadruplex ligands that target cancer stem cells

2010 - 2016 Scientific Support Programs for Cancer Research Grant-in-Aid for Scientific Research on Innovative Areas

2014 - 2016 ポリ(ADP-リボシル)化による細胞運動の制御とがんの浸潤・転移克服への応用

2011 - 2016 がん染色体・分裂期チェックポイントを標的とした治療法の確立(がん分子標的治療薬シーズとしてのタンキラーゼ阻害剤の探索開発)

2012 - 2014 Bioinformatics-based functional analysis of telomeric non-coding RNA

2011 - 2013 ポリ(ADPーリボシル)化による細胞の分裂と運動の制御

2011 - 2013 Role of oncogenic factors and their cooperations in survival of prostate tumor-propagating cells

2010 - 2012 Development of cancer molecular therapeutics that targets telomere-regulating factors

2010 - 2011 Lipid metabolomics to analyze the mechanisms for cellular adaptation to tumor microenvironment

2008 - 2009 Development of cancer molecular therapeutics directed to telomeres and cellular senescence svstems

2008 - 2009 がんの微小環境によるホルモン受容体制御と内分泌がんの生存機構

2005 - 2009 Development of an information-intensive basis for cancer chemotherapy

2007 - 2008 Multi-functions of tankyrase-1 in carcinogenesis

2006 - 2007 Elucidation of the consequence of telomere single-stand overhang, G-tail, in biology, and application to age-related disease

2006 - 2007 染色体末端の維持機構を標的とした癌分子治療法の開発

2005 - 2006 タンキラーゼ1・TAB182の生理機能とその制御機構

2006 - Conquest of hormone-refractory prostate cancers

2005 - 2005 染色体末端の維持機構を標的とした癌分子治療法の開発

2005 - Lipid metabolism in cancer

2004 - 2004 タンキラーゼによるテロメア長制御機構とテロメラーゼ阻害剤による制癌

2003 - 2004 タンキラーゼ・TAB182の生理機能とその制御機構

2003 - 2003 タンキラーゼによるテロメア長制御機構とテロメラーゼ阻害剤による制癌

1999 - 2000 白血病細胞におけるチロシンホスファターゼPTP-U2の発現調節と情報伝達

1999 - 1999 テロメラーゼ機能・テロメア維持機構の解明とその臨床応用

1999 - 1999 テロメラーゼ阻害剤による制癌と癌細胞におけるテロメラーゼ活性制御機構

1994 - 1999 がん細胞の薬剤感受性と抵抗性の分子機構とその制御

1996 - Functions and regulation mechanisms of anticancer molecular targets

1996 - Screening and development of novel anticancer drugs

1996 - Telomere maintenance system as a target for molecular cancer therapy

Show all

Papers (128)：

Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata, Shingo Dan, Hiroyuki Seimiya, Kensei Yamaguchi. Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer. Cancers. 2024. 16. 16
Ayane Nakamura, Tetsuo Mashima, Jin Lee, Saori Inaba, Naomi Kawata, Shun Morino, Koshi Kumagai, Kensei Yamaguchi, Hiroyuki Seimiya. Intratumor transforming growth factor-β signaling with extracellular matrix-related gene regulation marks chemotherapy-resistant gastric cancer. Biochemical and Biophysical Research Communications. 2024
Jin Lee, Tetsuo Mashima, Naomi Kawata, Noriko Yamamoto, Shun Morino, Saori Inaba, Ayane Nakamura, Koshi Kumagai, Takeru Wakatsuki, Kengo Takeuchi, et al. Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer. Cancer Research Communications. 2024
Shiho Hirose, Tetsuo Mashima, Xunmei Yuan, Makiko Yamashita, Shigehisa Kitano, Shinichi Torii, Toshiro Migita, Hiroyuki Seimiya. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma. Cancer Science. 2024
Shun Morino, Tetsuo Mashima, Fumiyuki Shirai, Satoshi Nagayama, Ryohei Katayama, Hiroyuki Seimiya. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer Letters. 2024. 584. 216632-216632

ｍore...

MISC (171)：

武川睦寛, 黒川顕, 醍醐弥太郎, 醍醐弥太郎, 鍋倉淳一, 清宮啓之. Need support for your KAKENHI research? Sure, we can!. 日本薬学会年会要旨集(Web). 2023. 143rd
目澤義弘, 醍醐弥太郎, 清宮啓之, 丸山玲緒, 折茂彰. Global histone deacetylation is a novel epigenetic alteration that mediates tumor-promoting abilities of carcinoma-associated fibroblasts. 日本結合組織学会学術大会抄録集. 2021. 53rd
馬島哲夫, 清宮啓之. Cancer stemness of drug-tolerant gastric cancer cells and their cell survival pathways. 実験医学. 2021. 39. 12
清宮啓之. 【がん研究10か年戦略の成果と課題-基礎から実用化までをつなぐ研究開発】基礎研究シーズ探索テロメア制御因子を標的とした革新的がん治療薬の開発. 医学のあゆみ. 2019. 271. 9. 781-787
清宮啓之. 【現代医学・生物学の先駆者たち】病理学・腫瘍学鶴尾隆(1943-2008) がん化学療法の研究. 生体の科学. 2019. 70. 5. 430-431

ｍore...

Patents (17)：

抗がん剤
新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤
VEGF-A/VEGFR2経路のdual inhibition療法、及びこれに使用する医薬組成物
TDP-43プロテイノパチーの治療薬並びに予防薬
新規化合物又はその薬理学的に許容される塩

ｍore...

Books (1)：

Drug discovery for cancer
Kagakudojin 2019 ISBN:9784759817331

Lectures and oral presentations (127)：

Telomere as the starting point of anticancer drug discovery
(LyonSE&N - ELyT Workshop 2020 2020)
テロメアから始まるがん創薬
(JSPS「日本におけるケミカルバイオロジーの新展開」に関する産学協力研究委員会 2019)
ケミカルツールを利用した四重鎖核酸の統合機能解析とその応用
(化学コミュニケーションのフロンティア第6回公開シンポジウム 2019)
Revisiting the paradoxical telomere shortening in cancer
(MBSJ2019 Workshop 2019)
Telomere as the starting point of anticancer drug discovery
(The 7th Symposium, RIKEN-Max Planck Joint Research Center 2019)

ｍore...

Education (2)：

1990 - 1995 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
1986 - 1990 The University of Tokyo Faculty of Pharmaceutical Sciences Department of Pharmacy

Professional career (1)：

Ph.D. (The University of Tokyo)

Work history (11)：

2020/04 - 現在 The University of Tokyo Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences Visiting Professor (concurrent)
2018/05 - 現在 RIKEN Program for Drug Discovery and Medical Technology Platforms Project Leader (concurrent)
2009/08 - 現在 The University of Tokushima Institute of Health Biosciences The University of Tokushima Graduate School Visiting Professor (concurrent)
2008/04 - 現在 Meiji Pharmaceutical University Graduate School of Pharmaceutical Sciences Visiting Professor (concurrent)
2005/01 - 現在 Japanese Foundation for Cancer Research Division of Molecular Biotherapy, Cancer Chemotherapy Center Member and Chief

Show all

Committee career (16)：

2017 - 現在 Journal of Biological Chemistry Editorial Board Member
2016/04 - 現在 Platform of Advanced Animal Model Support (AdAMS), Grant-in-Aid for Scientific Research on Innovative Areas, Ministry of Education, Culture, Sports, Science and Technology, Japan Member, General Management Group (2022-); Group Leader, Molecular Profiling Committee (2016-2022); Member of Executive Committee of the Technical Training Course for Young Scientists
2014 - 現在 Japanese Society of Medical Oncology Member of Education Planning Subcommittee (2014-2019); Member of Terminology Subcommittee (2015-2018); Member of Program Committee of the 14th Annual Meeting (2016)
2013 - 現在 Pharmaceuticals and Medical Devices Agency (PMDA) External Expert (2013-); Member of Working Group for Non-clinical Pharmacology Studies on Anticancer Drugs (2013, 2015-2016)
2009 - 現在 Japanese Association for RNA Interference Councilor (2009-); Chairman of Program Committee of the 4th Annual Meeting

2008 - 現在関東ホルモンと癌研究会幹事、第20回研究会当番幹事(2020年)

2007 - 現在 The JFCR International Symposium on Cancer Chemotherapy Executive Member, Committee Member (2007-); Chairman of Program Committee of the 16th Symposium

2006 - 現在 Anti-Tumor Drug Development Forum Executive Member

2006 - 現在 Japanese Cancer Association Vice President (Finance) (2023-); Director (2023-); Auditor (2020-2023); Councilor (2006-); Cancer Science Associate Editor (2007-); Secretary for Editor-in-Chief (2002-2008, 2021-); Member (2014-2019, 2024-) and Chairman (2016-2019) of COI Committee; International Sessions Organizing Committee (2008-2017); International Committee (2015-); Ethical Committee (2024-); Organizing Committee of the 11th AACR-JCA Joint Conference (2019); Program Committee of the 66th, 73rd, 75th-80th Annual Meetings

2005 - 現在 The Japanese Association for Molecular Target Therapy of Cancer Director (2014-2016, 2021-); Councilor; Member of Ethics and Conflict of Interest Committee (Chairman, 2021-); Member of Program Committee of the 15th, 16th, and 18th-24th Annual Meetings; Member of Executive Committee of the 9th-11th, 13th-16th Translational Research Workshops and the 1st Seeds Needs Workshop

2017/10 - 2023/09 Science Council of Japan Member; Secretary of Subcommittee of Cancer, Committee of Clinical Medicine

2013 - 2022 Nagoya International Cancer Treatment Symposium Advisor

2011 - 2021 Frontiers in Cancer Molecular Targets and Therapeutics Review Editor

2010/04 - 2016/03 Scientific Support Programs for Cancer Research, Grant-in-Aid for Scientific Research on Innovative Areas, Ministry of Education, Culture, Sports, Science and Technology, Japan Member (2005-2014), Group Leader (2015), Screening Committee of Anticancer Drugs; Executive Member of Young Scientist Workshop (2011-2015)

2011 - Japan Society for the Promotion of Science External Expert (2011 etc.); Commended External Expert (2017)

Journal of Cancer Research and Clinical Oncology Editorial Board

Show all

Awards (5)：

2019 - JFCR Academic Award
2017 - The Japanese Association for Molecular Target Therapy of Cancer Takashi Tsuruo Award
2016 - JCA-Mauvernay Award Telomere maintenance system as an anticancer therapeutic target
2004 - Japanese Cancer Association Incitement Award
2000 - NCI-JFCR Scientist Exchange Program Fellow Regulation of telomere dynamics by tankyrase

Association Membership(s) (10)：

Japanese Association for RNA Interference , Anti-Tumor Drug Development Forum , 関東ホルモンと癌研究会 , The Japanese Association for Molecular Target Therapy of Cancer , American Association for Cancer Research , Japanese Cancer Association , The JFCR International Symposium on Cancer Chemotherapy , Japanese Society of Medical Oncology , The Pharmaceutical Society of Japan , Molecular Biology Society of Japan

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page